Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 2:39 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 409 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Naltrexone Hydrochloride Clear all
Completed Phase 3 Interventional Results available

Evaluating Naltrexone for Use in Conjunction With Buprenorphine in Adults With Opioid Use Disorder Transitioning From Buprenorphine Maintenance Prior to First Dose of VIVITROL

NCT02696434
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Naltrexone, Placebo, Buprenorphine
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
9
States / cities
Lauderhill, Florida • Oakland Park, Florida • Winfield, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2019 · Synced Oct 6, 2026, 2:39 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study To Characterize The Pharmacokinetics Of Oxycodone In Healthy Volunteers

NCT01552863
View directory record Official record
Conditions
Pain
Interventions
Oxycodone
Drug
Lead sponsor
Pain Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 31, 2015 · Synced Oct 6, 2026, 2:39 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Adaptive Treatment for Alcohol and Cocaine Dependence

NCT01032135
View directory record Official record
Conditions
Substance Use Disorders
Interventions
Motivational Interviewing, Telephone counseling, Cognitive Behavioral Therapy (CBT) Counseling, medication management, Intensive OutPatient Therapy
Behavioral · Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 75 Years · Female only
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
3
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 5, 2017 · Synced Oct 6, 2026, 2:39 AM EDT
Completed Phase 2 Interventional Results available

The Effects of Naltrexone on Active Crohn's Disease

NCT00663117
View directory record Official record
Conditions
Inflammation, Crohn's Disease
Interventions
Naltrexone-HCl, Placebo
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 2, 2018 · Synced Oct 6, 2026, 2:39 AM EDT
Completed Phase 1 Interventional

Augmenting Zyprexa With Naltrexone to Ameliorate Metabolic Side-Effects

NCT00567034
View directory record Official record
Conditions
Schizophrenia, Psychotic Disorders
Interventions
naltrexone, placebo
Drug
Lead sponsor
Mclean Hospital
Other
Eligibility
21 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 25, 2013 · Synced Oct 6, 2026, 2:39 AM EDT
Completed Phase 4 Interventional Results available

Effectiveness of Naltrexone Versus Placebo to Reduce Craving for Alcohol With Evaluation of Genetic Variability.

NCT00366626
View directory record Official record
Conditions
Alcohol Dependence
Interventions
Naltrexone, Placebo
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
21 Years to 65 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jun 5, 2017 · Synced Oct 6, 2026, 2:39 AM EDT
Recruiting Phase 3 Interventional

Emergency Department-Initiated Medications for Alcohol Use Disorder

NCT05827159
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Naltrexone Pill, Naltrexone Injection, Brief Negotiation Interview, Gabapentin Pill
Drug · Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years to 80 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Oct 6, 2026, 2:39 AM EDT
Not listed Phase 2 Interventional

Enhanced Digital-Chemosensory-Based Olfactory Training for Remote Management of Substance Use Disorders

NCT06434818
View directory record Official record
Conditions
Substance Use Disorders, Opioid Use Disorder, Alcohol Use Disorder, Cocaine Use Disorder, Methamphetamine-dependence
Interventions
EDITOR (CBOT with olfactory stimulants, OFC tasks & remote monitoring of treatment compliance), CBOT with olfactory stimulants & OFC tasks, CBOT Sham
Combination Product
Lead sponsor
Evon Medics LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated May 30, 2024 · Synced Oct 6, 2026, 2:39 AM EDT
Completed Phase 4 Interventional

Naltrexone Treatment for Alcoholic Women

NCT00000448
View directory record Official record
Conditions
Alcoholism, Eating Disorder
Interventions
naltrexone, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2000
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 7, 2014 · Synced Oct 6, 2026, 2:39 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic and Safety Study of Naltrexone Release From Subcutaneous BICX104 Pellets Compared to Vivitrol Injections

NCT04828694
View directory record Official record
Conditions
Opioid-use Disorder
Interventions
BICX104, Vivitrol
Drug
Lead sponsor
BioCorRx Inc
Industry
Eligibility
18 Years to 50 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Tustin, California
Source: ClinicalTrials.gov public record
Updated Aug 16, 2023 · Synced Oct 6, 2026, 2:39 AM EDT
Recruiting Phase 2Phase 3 Interventional

Efficacy of Buprenorphine and XR-Naltrexone Combination for Relapse Prevention in Opioid Use Disorder

NCT05011266
View directory record Official record
Conditions
Opioid-use Disorder
Interventions
Buprenorphine/naloxone, Placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Rockville, Maryland • New York, New York
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Oct 6, 2026, 2:39 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Efficacy of Naltrexone in Women's Smoking Cessation

NCT00271024
View directory record Official record
Conditions
Smoking, Smoking Cessation
Interventions
Naltrexone (drug), Placebo (for Naltrexone)
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 65 Years
Enrollment
333 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2010
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 23, 2023 · Synced Oct 6, 2026, 2:39 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Understanding How Opioids Affect the Experiential and Neural Signatures of Social Experiences

NCT05007561
View directory record Official record
Conditions
Naltrexone, Placebo
Interventions
Naltrexone Hydrochloride, Placebo
Drug
Lead sponsor
San Diego State University
Other
Eligibility
18 Years to 25 Years
Enrollment
217 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 6, 2026, 2:39 AM EDT
Completed Phase 2 Interventional

Study To Examine Effect Of CP-866,087 On Consumption And Craving Of Alcohol In Alcohol Dependent Subjects.

NCT00147576
View directory record Official record
Conditions
Alcoholism
Interventions
CP-866,087
Drug
Lead sponsor
Pfizer
Industry
Eligibility
21 Years to 65 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
11
States / cities
Cerritos, California • New Haven, Connecticut • Washington D.C., District of Columbia + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2012 · Synced Oct 6, 2026, 2:39 AM EDT
Completed Phase 2 Interventional Results available

The Separate and Combined Effects of Vivitrol and Opiate Abstinence Reinforcement in the Treatment of Opioid Dependence

NCT01556425
View directory record Official record
Conditions
Opioid Dependence
Interventions
Vivitrol, Employment-based opiate abstinence reinforcement, Usual Care Control
Drug · Behavioral · Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 65 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 12, 2018 · Synced Oct 6, 2026, 2:39 AM EDT
Active, not recruiting No phase listed Observational

Weight Loss Management in Endometrial Cancer Survivors

NCT06877572
View directory record Official record
Conditions
Endometrial Cancer Survivors, Weight Management, Early Stage Endometrial Cancer
Interventions
Weight loss with pharmacotherapy, Weight loss without pharmacotherapy
Behavioral
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 6, 2026, 2:39 AM EDT
Completed Phase 1 Interventional

Effectiveness of Naltrexone and Lofexidine in Treating Detoxified Heroin Addicts - 1

NCT00218530
View directory record Official record
Conditions
Heroin Dependence
Interventions
Lofexidine
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 100 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Oct 6, 2026, 2:39 AM EDT
Completed Phase 2 Interventional Results available

Effects of Naltrexone on Nicotine Reinforcement

NCT00270231
View directory record Official record
Conditions
Tobacco Dependence
Interventions
Naltrexone, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 65 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 10, 2013 · Synced Oct 6, 2026, 2:39 AM EDT
Completed Phase 2Phase 3 Interventional

Low-Dose Naltrexone and Acetaminophen Combination and Sumatriptan in the Acute Treatment of Migraine With Nausea

NCT03185143
View directory record Official record
Conditions
Migraine With and Without Aura
Interventions
Naltrexone and Acetaminophen Combination, Sumatriptan 100 mg, Placebo
Drug
Lead sponsor
Allodynic Therapeutics, Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
North Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 14, 2021 · Synced Oct 6, 2026, 2:39 AM EDT
Active, not recruiting Not applicable Interventional

Virtual Reality Cognitive-Affective Training for Opioid Use Disorder- A Phase 2 RCT

NCT06021431
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
MORE-VR, Treatment as Usual
Device · Other
Lead sponsor
BehaVR LLC
Industry
Eligibility
18 Years and older
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
La Jolla, California • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 2, 2025 · Synced Oct 6, 2026, 2:39 AM EDT
Completed Phase 2 Interventional Results available

Naltrexone in the Treatment of Trichotillomania

NCT00775229
View directory record Official record
Conditions
Trichotillomania
Interventions
Naltrexone, Placebo
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 75 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 23, 2023 · Synced Oct 6, 2026, 2:39 AM EDT
Completed Phase 4 Interventional Results available

Understanding Treatment Response With Naltrexone Among White Alcoholics

NCT00817089
View directory record Official record
Conditions
Alcoholism
Interventions
Placebo Oral Tablet, Naltrexone
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
21 Years to 64 Years · Male only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 21, 2019 · Synced Oct 6, 2026, 2:39 AM EDT